EAU 2013 - Programme Book - YouMed

Saturday, 16 March - EAU Programme
Abstract Session
14.15 - 15.45 Diagnostics in early prostate cancer
Silver Hall - Level N2
Poster Session 12
Chairs: A. Govorov, Moscow (RU)
A. Villers, Lille (FR)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion. Extended presentations (*) are 4 minutes in length, followed
by 2 minutes for discussion.
133 PSA-pyramid in men with low range PSA: PCa incidence and mortality - a plea for risk-based prostate
cancer screening strategy in the European Randomized study of Screening for Prostate Cancer (ERSPC),
Aarau
M. Randazzo, D Seiler, J. Beatrice, M. Baumgartner, A. Huber, R. Grobholz, L. Manka, F. Recker,
M. Kwiatkowski (Aarau, Switzerland; Braunschweig, Germany)
134 Withdrawn
135 Psychological impact of PSA testing and biopsy using the impact of event scale
E.T. Kok, E.L. Turner, M.J. Davis, C. Metcalfe, J.A. Lane, D.E. Neal, F.C. Hamdy, J.L. Donovan (Utrecht, The
Netherlands; Bristol, Cambridge, Oxford, United Kingdom)
136 A randomized multicenter trial comparing 12 to 20-core prostate biopsy protocol
J. Irani, P. Blanchet, L. Salomon, P. Coloby, J. Hubert, B. Malavaud, N. Mottet (Poitiers, Guadeloupe, Creteil,
Pontoise, Nancy, Toulouse, Saint-Etienne, France)
137 PHI (Prostate Health Index) and %p2PSA for prediction of prostate cancer in men younger than 60 years of
age. A nested-case control study from PROpsa Multicentric European Study (PROMEtheuS project)
T. McNicholas, M. Lazzeri, A. Haese, A. De La Taille, J. Palou, G. Lughezzani, V. Scattoni, G. Lista, A. Larcher,
A. Cestari, N. Buffi, M. Freschi, L. Fowler, J.W. Roux, A. Renter, M. Graefen, P.O. Bosset, P. Le Corvoisier,
A. Breda, P. De La Torre, V. Bini, G. Guazzoni (Stevenage, United Kingdom; Milan, Perugia, Italy; Hamburg,
Germany; Creteil, France; Barcelona, Spain)
* 138 Standards in reporting of MRI-targeted prostate biopsies (START): Recommendations from an international
working party
V. Kasivisvanathan, C.M. Moore, S. Eggener, M. Emberton, J.F. Futterer, I. Gill, R. Grubb, B. Hadaschik,
L. Klotz, D. Margolis, L. Marks, J. Melamed, A. Oto, S. Palmer, P. Pinto, P. Pueche, S. Punwani,
A. Rosenkrantz, I. Shoots, R. Simon, S. Taneja, B. Turkbey, O. Ukimura, J. Van Der Meulen, A. Villers,
Y. Watanabe (London, Chicago, United Kingdom; Nijmegen, Rotterdam, The Netherlands; Los Angeles,
St Louis, New York, Chicago, Bethesda, United States of America; Heidelberg, Germany; Toronto, Canada;
Lille, France; Kurashiki, Japan)
139 Reducing unnecessary biopsies for suspicion of prostate cancer: Extension and validation of an ERSPC
based risk calculator with Phi
M.J. Roobol, D. Nieboer, A. Houlgatte, S. Vincendeau, M. Lazzeri, G. Guazzoni, C. Stephan, A. Semjonow,
A. Haese, M. Graefen, E.W. Steyerberg (Rotterdam, The Netherlands; Paris, Rennes, France; Milan, Italy;
Berlin, Munster, Hamburg, Germany)
140 Diabetes mellitus increases the risk of poorly differentiated tumor in prostate cancer patients
A. Nini, M. Sun, P.I. Karakiewicz, M. Bianchi, N.M. Passoni, A. Salonia, A. Galllina, F. Castiglione, N. Fossati,
R. Matloob, G. La Croce, F. Abdollah (Milan, Italy; Montreal, Canada)
EAU Milan 2013
119
Saturday